YONKERS, N.Y.--(BUSINESS WIRE)--Aureon Laboratories, Inc. announced today a research collaboration with the University of California, San Francisco (UCSF) to retrospectively analyze a Phase I clinical trial that examined the effects of neoadjuvant treatment with granulocyte macrophage colony stimulating factor (GM-CSF) prior to radical prostatectomy. The goal of the study will be to use Aureon’s Systems Pathology platform to identify histological, molecular, and clinical phenotypes within patient samples both pre and post treatment in order to construct models that assist in predicting therapeutic response. Aureon’s approach includes morphometric image analysis of histological specimens and cell-type specific, multiplexed molecular biomarkers. This information is integrated with clinical data using multivariate analysis and associated with clinical endpoints of interest.
